Back to top
more

Integra LifeSciences (IART)

(Real Time Quote from BATS)

$25.54 USD

25.54
444,565

-1.16 (-4.35%)

Updated Nov 7, 2024 03:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

IART vs. ABMD: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

IART vs. ABMD: Which Stock Is the Better Value Option?

Integra Launches AmnioExcel Placental Allograft Membrane

by Zacks Equity Research

The launch of this product is expected to boost Integra's (IART) OTT segment.

Integra LifeSciences Grows Organically Amid Supply Issues

by Zacks Equity Research

Integra LifeSciences' (IART) Codman Specialty Surgical segment registers impressive organic growth in Q4.

Integra (IART) Q4 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Integra's (IART) fourth-quarter 2019 results reflect strong segmental performances.

Integra Announces Preliminary Q4 Results, Share Buyback Plan

by Zacks Equity Research

Integra (IART) projects fourth-quarter 2019 revenues at or near the low end of its previously-announced guidance.

Here's Why You Should Retain Integra LifeSciences Stock Now

by Zacks Equity Research

Investors can hold on to Integra LifeSciences (IART) stock in their portfolio owing to solid prospects.

IART vs. TCMD: Which Stock Is the Better Value Option?

by Zacks Equity Research

IART vs. TCMD: Which Stock Is the Better Value Option?

Integra LifeSciences' (IART) Earnings Top Estimates in Q3

by Zacks Equity Research

We are upbeat about the year-over-year revenue growth in Integra LifeSciences' (IART) Codman Specialty Surgical segment.

Integra LifeSciences (IART) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of 4.62% and 0.66%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Integra LifeSciences (IART) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Integra Buys Rebound Therapeutics to Boost Neurosurgery Line

by Zacks Equity Research

Integra (IART) believes, Rebound's MIS technological arm will widen its neurosurgical pipeline within Codman Specialty Surgical space.

IART or GMED: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

IART vs. GMED: Which Stock Is the Better Value Option?

Integra LifeSciences' Organic Growth Strong on New Products

by Zacks Equity Research

Gaining traction from product unveilings and an improved sales force performance, Integra LifeSciences (IART) expects rapid organic growth in the second half of 2019.

Why Is Integra (IART) Down 1% Since Last Earnings Report?

by Zacks Equity Research

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Medtronic (MDT) Beats on Q1 Earnings, Ups FY20 EPS Guidance

by Zacks Equity Research

Medtronic (MDT) displays improved performances at CER, banking on growth across all major segmental businesses as well as geographies.

IART or GMED: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

IART vs. GMED: Which Stock Is the Better Value Option?

Moving Average Crossover Alert: Integra LifeSciences

by Zacks Equity Research

Integra LifeSciences Holdings Corporation (IART) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

IART vs. ABMD: Which Stock Is the Better Value Option?

by Zacks Equity Research

IART vs. ABMD: Which Stock Is the Better Value Option?

Integra Lifesciences' (IART) Earnings Top Estimates in Q2

by Zacks Equity Research

We are upbeat about Integra LifeSciences' (IART) year-over-year revenue growth across key business segments.

Integra LifeSciences (IART) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of 12.31% and 2.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Integra LifeSciences (IART) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Integra Partners AI-Driven Data Analytics Firm in Wound Care

by Zacks Equity Research

Integra LifeSciences (IART) expects its partnership with Tissue Analytics to be perfectly strategic as the latter's software solutions automatically derive high quality data from clinical pictures.

Veracyte (VCYT) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Veracyte (VCYT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

IART vs. ABMD: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

IART vs. ABMD: Which Stock Is the Better Value Option?

Integra LifeSciences' Organic Growth Strong on New Products

by Zacks Equity Research

Banking on product unveilings and a better sales force performance, Integra LifeSciences (IART) pins hopes on accelerated organic growth in the second half of 2019.